Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
- 16 April 2024
- journal article
- review article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 147, 107380
Abstract
No abstract availableKeywords
Funding Information
- Hubei Province Natural Science Foundation
- National Natural Science Foundation of China National Outstanding Youth Science Fund Project
- Hubei Provincial Department of Education
- Wuhan Institute of Technology
This publication has 106 references indexed in Scilit:
- Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitorsActa Pharmaceutica Sinica B, 2023
- Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS‐CoV‐2 Infection and COVID‐19ChemMedChem, 2022
- Advances and challenges in the pharmacokinetics and bioanalysis of chiral drugsChirality, 2022
- Omicron variant genome evolution and phylogeneticsJournal of Medical Virology, 2021
- SARS-CoV-2 cell entry and targeted antiviral developmentActa Pharmaceutica Sinica B, 2021
- Repurposing an Antiviral Drug against SARS‐CoV‐2 Main ProteaseAngewandte Chemie International Edition, 2021
- Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitorsActa Pharmaceutica Sinica B, 2021
- Combining High‐Throughput Synthesis and High‐Throughput Protein Crystallography for Accelerated Hit IdentificationAngewandte Chemie International Edition, 2021
- Coronaviruses: An Overview of Their Replication and Pathogenesis2015
- The substrate specificity of SARS coronavirus 3C-like proteinaseBiochemical and Biophysical Research Communications, 2005